Want to see KNSA full AI Analyst Report?
KNSA Stock Chart & Stats
$44.90
$0.18(0.88%)
At close: 4:00 PM EST
$44.90
$0.18(0.88%)
Day’s Range― - ―
52-Week Range$26.27 - $64.81
Previous CloseN/A
Volume84.12K
Average Volume (3M)521.21K
Market Cap
$4.92B
Enterprise Value$3.89B
Total Cash (Recent Filing)$468.09M
Total Debt (Recent Filing)$9.03M
Price to Earnings (P/E)65.4
Beta0.39
Next Earnings
Jul 28, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding46,303,276
10 Day Avg. Volume517,640
30 Day Avg. Volume521,214
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)5.39
Price to Sales (P/S)4.52
P/FCF Ratio120.45
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue5.16
Enterprise Value/Gross Profit9.45
Enterprise Value/Ebitda36.17
Forecast
1Y Price Target
$65.86Price Target Upside46.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.38
Revenue Forecast (FY)$939.49M
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Cash GenerationSustained TTM operating profit and free cash flow (~$164M) signal durable internal funding for commercial expansion and R&D without reliance on external financing. Reliable cash generation supports reinvestment, flexibility vs. payor headwinds and lowers refinancing risk over the medium term.
Conservative Balance Sheet, Minimal LeverageExtremely low debt levels and a strong equity base give the company long-term financial flexibility to invest in commercialization and pipeline work, absorb commercial volatility, and fund clinical programs without immediate pressure to raise dilutive capital, enhancing durability.
Commercial Momentum And Expanding Prescriber BaseRobust ARCALYST growth, rising prescribers (>4,550 with ~400 new in Q1) and raised 2026 revenue guidance reflect durable commercial traction. High prescription conversion on patient inquiries (~80%) plus targeted DTC initiatives increase likelihood of sustained adoption and revenue scalability over the coming months.
Bears Say
Historical Earnings And Cash-flow VolatilityA history of year-to-year swings in profitability and cash flow undermines predictability of future earnings and planning. Even with a strong recent run-rate, this cyclicality raises execution risk for funding growth and makes long-term forecasting and capital allocation more uncertain for stakeholders.
Gross-to-net And Payer Dynamics RiskPersistent payor pressure and shifting co-pay support alter realized revenue and margins. Gross-to-net volatility can materially swing net sales from quarter to quarter, reducing revenue visibility and requiring continued commercial spend to secure access, a structural headwind to durable margin improvement.
Clinical Dose-selection Uncertainty (KPL-387)Unresolved dose selection for KPL-387 leaves timing and success of Phase III and eventual approval uncertain. This creates structural pipeline execution risk that could delay launch-readiness, cash-flow contribution from the program, and strategic planning tied to a once-monthly formulation.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals Ltd. Class A’s price range in the past 12 months?
Kiniksa Pharmaceuticals Ltd. Class A lowest stock price was $26.27 and its highest was $64.81 in the past 12 months.
What is Kiniksa Pharmaceuticals Ltd. Class A’s market cap?
Kiniksa Pharmaceuticals Ltd. Class A’s market cap is $4.92B.
When is Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date?
Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date is Jul 28, 2026 which is in 26 days.
How were Kiniksa Pharmaceuticals Ltd. Class A’s earnings last quarter?
Kiniksa Pharmaceuticals Ltd. Class A released its earnings results on Apr 28, 2026. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.202 by $0.068.
Is Kiniksa Pharmaceuticals Ltd. Class A overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals Ltd. Class A’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals Ltd. Class A pay dividends?
Kiniksa Pharmaceuticals Ltd. Class A does not currently pay dividends.
What is Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate?
Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate is 0.31.
How many shares outstanding does Kiniksa Pharmaceuticals Ltd. Class A have?
Kiniksa Pharmaceuticals Ltd. Class A has 46,303,276 shares outstanding.
What happened to Kiniksa Pharmaceuticals Ltd. Class A’s price movement after its last earnings report?
Kiniksa Pharmaceuticals Ltd. Class A reported an EPS of $0.27 in its last earnings report, beating expectations of $0.202. Following the earnings report the stock price went up 23.481%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals Ltd. Class A?
Currently, no hedge funds are holding shares in KNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.86 (46.68% Upside)
$65.86 (46.68% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.57%
12-Months-Change
Fundamentals
Return on Equity
13.26%
Trailing 12-Months
Asset Growth
37.70%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals Ltd. Class A
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
KNSA Company Deck
KNSA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: strong Q1 commercial performance with 56% YoY ARCALYST revenue growth, raised full-year guidance, expanding collaboration profit, improved net income, and healthy cash generation. Commercial execution (new prescribers and patient enrollments) and a targeted DTC initiative underpin future growth. The pipeline also showed clear near-term milestones (KPL-387 dose data in H2 2026, Phase III start by year-end, and KPL-1161 Phase I planned). Offsetting items include gross-to-net/ co-pay variability, higher operating expenses tied to growth investments, remaining low patient awareness (requiring continued marketing investment), and the need to confirm Phase II dose selection for KPL-387. Overall, the positives significantly outweigh the challenges.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$65.86
▲(46.68% Upside)
Technical Analysis
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
CG Oncology, Inc.
―
Ownership Overview
9.13% Insiders
24.15% Mutual Funds
36.29% Other Institutional Investors
17.10% Public Companies and
Individual Investors